AsiaNews

Strides Pharma Science arm gets US FDA nod for Ethacrynic Acid tabs

The drug is used to treat fluid retention (edema)

Strides Pharma Science said its step down subsidiary has received approval from the US health regulator for Ethacrynic Acid tablets, used to treat fluid retention (edema).

THIS CAN BE YOUR ADVERTISEMENT

The approved product is a generic version of Edecrin tablets, 25 mg, of Bausch Health Americas.

Strides Pharma Global, Singapore, has received approval for Ethacrynic Acid tablets USP in the strengths of 25 mg from the United States Food and Drug Administration (USFDA), Strides Pharma Science said in a regulatory filing.

Quoting IQVIA moving annual total (MAT) August 2020 data, Strides Pharma Science said the US market for Ethacrynic Acid tablets USP, 25 mg, is approximately $ 14 million.

The product will be manufactured at the company’s flagship facility at Bengaluru and will be marketed by Strides Pharma in the US market, the company added.

The company has 126 cumulative abbreviated new drug application (ANDA) filings with the US FDA of which 92 ANDAs have been approved and 34 are pending for approval.

Ethacrynic acid is in a class of medications called diuretics (water pills). It is used to treat edema (excess fluid held in body tissues) in adults and children caused by medical problems such as cancer, heart, kidney, or liver disease.

 

PTI

 

Support us in our endeavor to bring you Advertisement free content.
Choose your options to donate or subscribe.

Tags

Related Articles

Leave a Reply

Back to top button
Close
Close